2023
Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Sofen H, Strober B, Imafuku S, Paul C, Gooderham M, Spelman L, Seo S, Passeron T, Kisa R, Berger V, Vritzali E, Hoyt K, Colombo M, Banerjee S, Augustin M, Stein Gold L, Alexis A, Thaçi D, Blauvelt A, Lebwohl M. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal Of Cutaneous Medicine 2023, 7: s241. DOI: 10.25251/skin.7.supp.241.Peer-Reviewed Original ResearchPASI 75 respondersSevere plaque psoriasisPASI 75PASI 90Week 148Plaque psoriasisWeek 52Week 16Week 24Parent trialClinical efficacyDay 1Response rateLong-term extension trialsNew safety signalsPhase 3 trialSubset of patientsMaintenance of responseLong-term efficacyLong-term effectivenessNonresponder imputationOral placeboPsoriasis AreaExtension trialSafety signalsPS14 Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial
Warren R, Strober B, Lebwohl M, Foley P, Langley R, Davis L, Hoepken B, Szilagyi B, Ciaravino V, Bewley A. PS14 Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial. British Journal Of Dermatology 2023, 188: ljad113.366. DOI: 10.1093/bjd/ljad113.366.Peer-Reviewed Original ResearchOpen-label extensionBody surface areaSevere plaque psoriasisWeek 16Plaque psoriasisOpen-label extension trialTreatment-related adverse eventsDermatology Life Quality IndexPASI 90 responseMaintenance of efficacyHealth-related qualityYear 3Long-term efficacyLife Quality IndexLack of efficacyYear 1HRQoL benefitsNonresponder imputationOLE entryPsoriasis AreaResponder rateAdverse eventsWeek 24Study treatmentAnalysed patientsP169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Lisse J, Pustizzi J, Sapin C, Bolce R, Ritchlin C. P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis. Rheumatology 2023, 62 DOI: 10.1093/rheumatology/kead104.210.Peer-Reviewed Original ResearchNail Psoriasis Severity IndexProportion of patientsPsoriatic arthritisWeek 24Nail diseaseNail involvementDIP involvementSanofi GenzymeWeek 52Total scoreEli LillyExact testNail bedUCB PharmaDistal interphalangeal (DIP) joint diseaseDistal interphalangeal joint involvementDifferent biological therapiesInterphalangeal joint involvementNail matrix involvementPsoriatic nail diseasePost-baseline assessmentPsoriasis Severity IndexNHS Greater GlasgowFisher's exact testTotal maximum scoreSafety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
Thaçi D, Vender R, de Rie M, Conrad C, Pariser D, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball A. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. British Journal Of Dermatology 2023, 188: 22-31. PMID: 36689515, DOI: 10.1093/bjd/ljac021.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsOpen-label extensionSevere plaque psoriasisWeek 104Week 24PASI 100PASI 90Plaque psoriasisWeek 16Safety dataCommon treatment-emergent adverse eventsSerious treatment-emergent adverse eventsUpper respiratory tract infectionInitial randomization groupUnexpected safety findingsNew safety signalsRespiratory tract infectionsWeeks of treatmentLong-term resultsBaseline PASIBimekizumab groupBRIGHT trialMaintenance dosingPsoriasis AreaSafety findings
2022
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Kokolakis G, Warren R, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Gomez N, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. British Journal Of Dermatology 2022, 188: 330-340. PMID: 36751950, DOI: 10.1093/bjd/ljac089.Peer-Reviewed Original ResearchConceptsExposure-adjusted incidence ratesTreatment-emergent adverse eventsAdverse eventsDurable improvementMajority of TEAEsDiscontinuation of biologicsNew safety findingsPASI 90 respondersSevere plaque psoriasisHealth-related qualityBody surface areaTime of switchAbsolute PASIIIIb trialPASI 100PASI 90Skin clearancePlaque psoriasisWeek 48Clinical responseEfficacy outcomesPsoriasis AreaSafety findingsWeek 24Week 52AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
Warren R, Armstrong A, Gooderham M, Strober B, Thaçi D, Imafuku S, Sofen H, Spelman L, Korman N, Zheng M, Colston E, Throup J, Kundu S, Kisa R, Banerjee S, Blauvelt A. AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. Annals Of The Rheumatic Diseases 2022, 81: 1570-1571. DOI: 10.1136/annrheumdis-2022-eular.1377.Peer-Reviewed Original ResearchSevere plaque psoriasisGrant/research supportDermatology Life Quality IndexBristol-Myers SquibbPASI 75 responseSanofi GenzymeWeek 52PASI 75Plaque psoriasisGlobal assessment scoreWeek 16LEO PharmaPersonal feesKyowa Hakko KirinWeek 24Tyrosine kinase 2Boehringer IngelheimLecture feesPASI 90Psoriasis RegistrySymptom scoresSpeakers bureauEli LillyStatic Physician's Global Assessment scorePhysician Global Assessment score
2021
POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
Armstrong A, Gooderham M, Warren R, Papp K, Strober B, Thaçi D, Colston E, Throup J, Kundu S, Banerjee S, Blauvelt A. POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY. Annals Of The Rheumatic Diseases 2021, 80: 795.1-796. DOI: 10.1136/annrheumdis-2021-eular.1002.Peer-Reviewed Original ResearchSevere plaque psoriasisKyowa Hakko KirinGrant/research supportBristol-Myers SquibbCommon adverse eventsCorrona Psoriasis RegistryPlaque psoriasisAdverse eventsSanofi GenzymeWeek 16Merck SeronoLEO PharmaPASI 75Meiji Seika PharmaPersonal feesTyrosine kinase 2Boehringer IngelheimMerck SharpPsoriasis RegistryWeek 24Psoriatic arthritisSpeakers bureauEli LillyJanssen-CilagUpper respiratory tract infection
2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
Strober B, Gottlieb A, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl M. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal Of The American Academy Of Dermatology 2017, 76: 655-661. PMID: 28087133, DOI: 10.1016/j.jaad.2016.11.043.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatologic AgentsDouble-Blind MethodEtanerceptFemaleHumansImmunosuppressive AgentsInjections, SubcutaneousInterleukin-17MaleMiddle AgedPatient SatisfactionPsoriasisQuality of LifeRecurrenceSurveys and QuestionnairesTreatment OutcomeTumor Necrosis Factor-alphaConceptsDermatology Life Quality IndexWeek 24Secukinumab treatmentWeek 52Phase III randomized placebo-controlled clinical trialsRandomized placebo-controlled clinical trialPatient-reported health-related qualityPlacebo-controlled clinical trialGreater sustained improvementsGreater clinical responseHealth-related qualityLife Quality IndexProportion of subjectsQuality of lifeSevere psoriasisClinical responsePlacebo comparisonPsoriasis AreaMedian timePatients' qualityWeek 12Chronic conditionsOutcome benefitsSafe treatmentClinical trials
2012
A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
Gottlieb A, Langley R, Strober B, Papp K, Klekotka P, Creamer K, Thompson E, Hooper M, Kricorian G. A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. British Journal Of Dermatology 2012, 167: 649-657. PMID: 22533447, PMCID: PMC3504074, DOI: 10.1111/j.1365-2133.2012.11015.x.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisCombination therapyAdverse eventsWeek 24Etanercept monotherapyMonotherapy groupPlaque psoriasisWeek 12Necrosis factor inhibitor therapyStatic Physician's Global AssessmentGlobal assessmentMethotrexate combination therapyPhysician global assessmentPlacebo-controlled studySerious adverse eventsCombination therapy groupProportion of patientsAddition of methotrexatePASI 50PASI 75PASI 90Primary endpointSevere psoriasisAcceptable tolerabilityPsoriasis Area
2006
Comparison of Tazarotene and Minocycline Maintenance Therapies in Acne Vulgaris: A Multicenter, Double-blind, Randomized, Parallel-Group Study
Leyden J, Thiboutot D, Shalita A, Webster G, Washenik K, Strober B, Shupack J. Comparison of Tazarotene and Minocycline Maintenance Therapies in Acne Vulgaris: A Multicenter, Double-blind, Randomized, Parallel-Group Study. JAMA Dermatology 2006, 142: 605-612. PMID: 16702498, DOI: 10.1001/archderm.142.5.605.Peer-Reviewed Original ResearchConceptsGreater global improvementMaintenance therapyTazarotene gelGlobal improvementLesion countsAcne vulgarisOpen-label treatment phaseParallel-group studyInflammatory lesion countSevere acne vulgarisOverall disease severityPlacebo capsulesMaintenance regimensReferral centerWeek 24Severe acneVehicle gelAmbulatory patientsWeek 12Minocycline therapyAntibiotic exposureMean reductionTreatment phasePatientsGreater efficacy